Conditions · Pancreatic cancer
Pancreatic cancer — clinical trials in Netherlands
30 open options
- TRIALPHASE2RECRUITING
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran · Atezolizumab · mFOLFIRINOX — 89 sites
- TRIALNAENROLLING_BY_INVITATION
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
Standardized surveillance — 11 sites
- TRIALEARLY_PHASE1RECRUITING
PET-imaging of Two Vartumabs in Patients With Solid Tumors
89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv · PET/CT scan — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Elironrasib · Daraxonrasib — 55 sites
- TRIALPHASE4RECRUITING
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
HOP bundle — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Pembrolizumab · Folfirinox · SABR — 4 sites
- TRIALPHASE3RECRUITING
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101 · Everolimus · Sunitinib — 54 sites
- TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
- TRIALNARECRUITING
Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy
Additional stereotactic body radiation therapy — 3 sites
- TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
AZD5863 — 25 sites
- TRIALNANOT_YET_RECRUITING
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
MR guided radiotherapy — 4 sites
- TRIALPHASE1RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
LY4337713 — 30 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
- TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
- TRIALPHASE1 / PHASE2RECRUITING
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
CP-506 · Carboplatin · Immune checkpoint inhibitor — 5 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ersodetug — 13 sites
- TRIALPHASE2RECRUITING
NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101
Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101 — 1 site
- TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 86 sites
- TRIALPHASE1 / PHASE2RECRUITING
Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
Durvalumab · Rintatolimod — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles) — 10 sites
- TRIALNARECRUITING
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)
Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires. — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Risvutatug Rezetecan · Drug 1 · Drug 2 — 85 sites
- TRIALNARECRUITING
Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
High-dose-high precision MR-guided radiotherapy — 1 site
- TRIALNARECRUITING
Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)
Laparoscopic minimally invasive left-sided pancreatecomy · Robot-assisted minimally invasive left-sided pancreatecomy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ifinatamab deruxtecan — 120 sites
- TRIALPHASE1 / PHASE2RECRUITING
CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer
CT-guided percutaneous intratumoural implantation of the OncoSil™ device — 1 site
- TRIALPHASE4RECRUITING
Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
Cefuroxime · Metronidazole — 11 sites
- TRIALNARECRUITING
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
Preoperative optimisation program — 13 sites
- TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
[68Ga]Ga-NNS309 · [177Lu]Lu-NNS309 — 29 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.